Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Strong evidence supports their efficacy in inducing clinically meaningful weight loss in individuals with overweight or obesity
In mouse fertility studies with exenatide, the active ingredient in BYDUREON, at twice-daily subcutaneous doses of 6, 68, or 760 mcg/kg/day, males were treated for 4 weeks prior to and throughout mating, and females were treated 2 weeks prior to mating and throughout mating until gestation day 7
At present, the Food and Drug Administration (FDA) has approved some anti-obesity drugs, including GLP-1RA liraglutide and semaglutide
Scientific Reports 8(1):5804
Benefits for Moderation and Abstinence Goals Reduction in Cravings and Alcohol Intake: GLP-1 agonists appear to attenuate reward responses to alcohol, making it easier for people to feel satisfied before they pass their off switch and drink more than intended
